CN104662017A - 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途 - Google Patents

酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途 Download PDF

Info

Publication number
CN104662017A
CN104662017A CN201380047770.5A CN201380047770A CN104662017A CN 104662017 A CN104662017 A CN 104662017A CN 201380047770 A CN201380047770 A CN 201380047770A CN 104662017 A CN104662017 A CN 104662017A
Authority
CN
China
Prior art keywords
luliconazole
pharmaceutical preparation
composition
amide derivatives
growing amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380047770.5A
Other languages
English (en)
Chinese (zh)
Inventor
增田孝明
山口博志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Publication of CN104662017A publication Critical patent/CN104662017A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201380047770.5A 2012-09-14 2013-02-19 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途 Pending CN104662017A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-202696 2012-09-14
JP2012202696A JP5460797B1 (ja) 2012-09-14 2012-09-14 アミド誘導体及び安定性指標としてのその使用
PCT/JP2013/055025 WO2014041825A1 (en) 2012-09-14 2013-02-19 Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation

Publications (1)

Publication Number Publication Date
CN104662017A true CN104662017A (zh) 2015-05-27

Family

ID=47884458

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380047770.5A Pending CN104662017A (zh) 2012-09-14 2013-02-19 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途

Country Status (7)

Country Link
US (1) US9145401B2 (cg-RX-API-DMAC10.html)
EP (1) EP2895480A1 (cg-RX-API-DMAC10.html)
JP (1) JP5460797B1 (cg-RX-API-DMAC10.html)
CN (1) CN104662017A (cg-RX-API-DMAC10.html)
IN (1) IN2015DN02930A (cg-RX-API-DMAC10.html)
RU (1) RU2612557C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014041825A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5688406B2 (ja) 2009-04-09 2015-03-25 株式会社ポーラファルマ 抗真菌医薬組成物
WO2010117089A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
US8952044B2 (en) 2009-08-25 2015-02-10 Pola Pharma Inc. Antimycotic pharmaceutical composition
WO2011155640A1 (en) 2010-06-11 2011-12-15 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN104619703A (zh) 2012-09-14 2015-05-13 宝丽制药股份有限公司 具有结晶习性的晶体以及通过对所述晶体进行加工获得的药物组合物
US9068958B1 (en) 2012-09-14 2015-06-30 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and pharmaceutical composition prepared by containing the crystal
RU2622644C2 (ru) 2012-09-14 2017-06-19 Пола Фарма Инк. Кристаллическое вещество и содержащий его фармацевтический препарат
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5680161B1 (ja) 2013-09-06 2015-03-04 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5587488B1 (ja) * 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5926756B2 (ja) * 2014-03-26 2016-05-25 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5623671B1 (ja) * 2014-07-23 2014-11-12 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
WO2016092478A1 (en) * 2014-12-12 2016-06-16 Glenmark Pharmaceuticals Limited Process for preparation of luliconazole
US12270740B2 (en) * 2019-02-07 2025-04-08 Shimadzu Corporation Analysis method, analysis device and non-transitory computer readable recording medium storing program

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2005958A1 (en) * 2006-03-08 2008-12-24 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
WO2011155640A1 (en) * 2010-06-11 2011-12-15 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN102395274A (zh) * 2009-02-13 2012-03-28 托派卡医药股份有限公司 抗真菌制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3081766B2 (ja) 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
ZA965745B (en) 1995-07-08 1997-01-27 Nihon Hohyaku Co Ltd Antifungal agent compound therefor process for producing the same and method for using the same
JP2002114680A (ja) 2000-07-31 2002-04-16 Nippon Nohyaku Co Ltd 抗真菌剤
RU2419429C2 (ru) 2006-03-08 2011-05-27 Нихон Нохияку Ко.,Лтд. Фармацевтическая композиция для наружного применения
US8058303B2 (en) 2006-03-08 2011-11-15 Nihon Nohyaku Co, Ltd Pharmaceutical composition for external use
US20100173965A1 (en) 2007-09-05 2010-07-08 Pola Pharma Inc. Antifungal composition
CN101808637B (zh) 2007-09-05 2013-07-24 宝丽制药股份有限公司 医药组合物
JP5453093B2 (ja) 2007-09-05 2014-03-26 株式会社ポーラファルマ 抗真菌医薬組成物
JP5688406B2 (ja) 2009-04-09 2015-03-25 株式会社ポーラファルマ 抗真菌医薬組成物
WO2010117089A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
US8952044B2 (en) 2009-08-25 2015-02-10 Pola Pharma Inc. Antimycotic pharmaceutical composition
US9068958B1 (en) 2012-09-14 2015-06-30 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and pharmaceutical composition prepared by containing the crystal
CN104619703A (zh) 2012-09-14 2015-05-13 宝丽制药股份有限公司 具有结晶习性的晶体以及通过对所述晶体进行加工获得的药物组合物
RU2621615C2 (ru) 2012-09-14 2017-06-06 Пола Фарма Инк. Фармацевтическая композиция, содержащая луликоназол
RU2622644C2 (ru) 2012-09-14 2017-06-19 Пола Фарма Инк. Кристаллическое вещество и содержащий его фармацевтический препарат
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5587488B1 (ja) * 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2005958A1 (en) * 2006-03-08 2008-12-24 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
EP2005958A4 (en) * 2006-03-08 2010-09-15 Nihon Nohyaku Co Ltd TOPICAL PHARMACEUTICAL COMPOSITION
CN102395274A (zh) * 2009-02-13 2012-03-28 托派卡医药股份有限公司 抗真菌制剂
WO2011155640A1 (en) * 2010-06-11 2011-12-15 Pola Pharma Inc. Antimycotic pharmaceutical composition

Also Published As

Publication number Publication date
IN2015DN02930A (cg-RX-API-DMAC10.html) 2015-09-18
RU2015113587A (ru) 2016-11-10
JP2014058449A (ja) 2014-04-03
JP5460797B1 (ja) 2014-04-02
EP2895480A1 (en) 2015-07-22
RU2612557C2 (ru) 2017-03-09
US9145401B2 (en) 2015-09-29
US20150191456A1 (en) 2015-07-09
WO2014041825A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
CN104662017A (zh) 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途
JP6215102B2 (ja) 医薬組成物
CA2760084C (en) 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
KR101343291B1 (ko) 외용의 의약 조성물
WO2020028820A1 (en) Topical compositions and methods of preparation and use
AU2017277524B2 (en) Topical formulations of PDE-4 inhibitors and their methods of use
HUE035882T2 (en) 1,2,4-triazolo [4,3-A] pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
JP2015114210A (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
JP2008303194A (ja) 香料造粒物
DE60119378T2 (de) Benzofuranderivate und pharmazeutische zusammensetzungen, die diese enthalten
JP5623671B1 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
JP2009280573A (ja) 内服用体臭抑制剤
WO2025240802A1 (en) Novel compositions, devices and methods
WO2025078256A1 (en) Composition
JP6067399B2 (ja) 医薬組成物
WO2025240804A1 (en) Novel compositions, devices and methods
JP6077081B2 (ja) 医薬組成物
JP5719985B2 (ja) ジフェニルメチルピペラジン誘導体
KR20180030025A (ko) 질환의 치료를 위한 헤테로아릴 카보나이트릴
CN121013710A (zh) 包括激酶抑制剂的局部医药制品
JP5709499B2 (ja) リボフラビン又はその誘導体の安定化
JP2014152135A (ja) 医薬組成物
JP2010120874A (ja) ジフェニルメチルピペラジン誘導体及び該誘導体を含有する医薬
KR20170137117A (ko) 피부용의 의약 조성물
JPWO2015152168A1 (ja) 軟膏基剤および軟膏

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150527